JAGX
Price
$5.51
Change
-$0.10 (-1.78%)
Updated
Apr 17 closing price
Capitalization
3.62M
SRPT
Price
$53.79
Change
-$0.15 (-0.28%)
Updated
Apr 17 closing price
Capitalization
5.22B
12 days until earnings call
Ad is loading...

JAGX vs SRPT

Header iconJAGX vs SRPT Comparison
Open Charts JAGX vs SRPTBanner chart's image
Jaguar Health
Price$5.51
Change-$0.10 (-1.78%)
Volume$10.35K
Capitalization3.62M
Sarepta Therapeutics
Price$53.79
Change-$0.15 (-0.28%)
Volume$1.91M
Capitalization5.22B
JAGX vs SRPT Comparison Chart
Loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAGX vs. SRPT commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and SRPT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (JAGX: $5.51 vs. SRPT: $53.79)
Brand notoriety: JAGX: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 24% vs. SRPT: 87%
Market capitalization -- JAGX: $3.62M vs. SRPT: $5.22B
JAGX [@Biotechnology] is valued at $3.62M. SRPT’s [@Biotechnology] market capitalization is $5.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 1 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • JAGX’s FA Score: 1 green, 4 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, both JAGX and SRPT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 6 TA indicator(s) are bullish while SRPT’s TA Score has 5 bullish TA indicator(s).

  • JAGX’s TA Score: 6 bullish, 2 bearish.
  • SRPT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, JAGX is a better buy in the short-term than SRPT.

Price Growth

JAGX (@Biotechnology) experienced а +7.62% price change this week, while SRPT (@Biotechnology) price change was +6.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

JAGX is expected to report earnings on May 19, 2023.

SRPT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRPT($5.22B) has a higher market cap than JAGX($3.62M). SRPT has higher P/E ratio than JAGX: SRPT (22.99) vs JAGX (0.01). SRPT YTD gains are higher at: -55.761 vs. JAGX (-78.178). SRPT has higher annual earnings (EBITDA): 317M vs. JAGX (-29.1M). SRPT has more cash in the bank: 1.36B vs. JAGX (13.3M). JAGX has less debt than SRPT: JAGX (34.3M) vs SRPT (1.34B). SRPT has higher revenues than JAGX: SRPT (1.9B) vs JAGX (10.5M).
JAGXSRPTJAGX / SRPT
Capitalization3.62M5.22B0%
EBITDA-29.1M317M-9%
Gain YTD-78.178-55.761140%
P/E Ratio0.0122.990%
Revenue10.5M1.9B1%
Total Cash13.3M1.36B1%
Total Debt34.3M1.34B3%
FUNDAMENTALS RATINGS
JAGX vs SRPT: Fundamental Ratings
JAGX
SRPT
OUTLOOK RATING
1..100
2261
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9946
PRICE GROWTH RATING
1..100
9896
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (14) in the Pharmaceuticals Generic industry is somewhat better than the same rating for SRPT (67) in the Biotechnology industry. This means that JAGX’s stock grew somewhat faster than SRPT’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SRPT (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (46) in the Biotechnology industry is somewhat better than the same rating for JAGX (99) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew somewhat faster than JAGX’s over the last 12 months.

SRPT's Price Growth Rating (96) in the Biotechnology industry is in the same range as JAGX (98) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew similarly to JAGX’s over the last 12 months.

SRPT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew similarly to JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXSRPT
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
64%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
77%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
69%
View a ticker or compare two or three
Ad is loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AFRM42.101.34
+3.29%
Affirm Holdings
PBT9.800.19
+1.98%
Permian Basin Royalty Trust
AENT2.81-0.01
-0.35%
Alliance Entertainment Holding Corp
ZCMD1.19-0.01
-0.83%
Zhongchao
IDCC189.27-7.71
-3.91%
InterDigital

JAGX and

Correlation & Price change

A.I.dvisor tells us that JAGX and HEPA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and HEPA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-1.81%
HEPA - JAGX
29%
Poorly correlated
-6.09%
DVHGF - JAGX
27%
Poorly correlated
N/A
AFMD - JAGX
26%
Poorly correlated
+1.03%
SNPX - JAGX
26%
Poorly correlated
-5.37%
SLNO - JAGX
26%
Poorly correlated
+0.07%
More